| Price | $39.74 |
| Year Range | $39.51 – $46.64 |
| Market Cap | $96B |
| PE Ratio | 21.2 |
| Industry | Drug Manufacturers |
What Is Sanofi’s AI Stock Analysis?
Sanofi’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Sanofi’s momentum in near-real time.
Sanofi (SNY) has an AltIndex AI Score of 62/100, currently a Buy signal. The AI Score distills Sanofi's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Sanofi’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Sanofi — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving SNY’s AI Score?
Fundamentals
Revenue for the last quarter was $12.3B. This is an increase of 9.39% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 14.58%, suggesting positive year-over-year growth. Net income for the last quarter was $343M. This represents a decrease of 78.75% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 91.29%, which may be a cause for concern. Ebitda for the last quarter was $1.68B. This represents a decrease of 38.29% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 11.28%, which may be a cause for concern. The current P/E ratio is 21.2. This appears to be within a normal range, neither particularly high nor low.
See Sanofi’s earnings and insider transactions.
Technicals
Today's stock price is $39.74. This represents a decrease of 7.08% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 14.76%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $39.91, which is lower than the previous SMA10 of $39.93. This suggests a potential downward trend in price movement. The RSI is 64.4, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Sanofi has an estimated 977 open positions. This number is down by -18% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Sanofi is neutral. Sanofi has an estimate of 910,000 visitors to their webpage. The number of visitors is up by 19% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Sanofi’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is very high, a positive sign. Sanofi has 110,000 followers on their Instagram page. The number of followers is up by 4% in the last couple of months, indicating an increased interest in the company. Sanofi has 150,000 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.
Track Sanofi’s market sentiment.
Frequently Asked Questions: Sanofi AI Stock Analysis
Sanofi's AltIndex AI Score is 62/100, currently a Buy signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Sanofi a Buy (62/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Sanofi — company overview, fundamentals, technicals and alternative data, with a recommendation. See the SNY AI Score or sign up to read the full thesis.
